DCFN - Bio reads the bio-literature alongside its citation graph + pathway data and surfaces structural gaps in biomarker / mechanism research — where reproducibility is at risk, where the next translational bet is structurally plausible, and which load-bearing foundations are citation-stale vs absorbed-into-the-field. The engine doesn't run trials. It surfaces where the trials should land.
Learn moreEvery audit pulls live citations from public bio-literature data. When DCFN-Bio flags a paper as a load-bearing foundation, it can show you the citation chain, the methodology overlap, and the structural reasoning — not just a relevance score.
Primary literature corpus via NCBI E-utilities. Full citation graph + abstract text + MeSH terms.
Pathway and mechanism databases. Used to anchor the engine's structural reading of mechanism claims to validated pathway topology.
Biomarker name, mechanism description, pathway, or specific paper(s) you want audited. Open-text input.
$85 unlocks a 30-day window on the engine's Pro execution tier. Submit any biomarker / mechanism / pathway query (open text). Layer 1 landscape briefing + Layer 2 Methodology Audit (TPP alignment, T1-T4 translational stage mapping, pre-analytical variable flag, reproducibility risk profile) included — no per-deliverable charges during the window.
Stripe handles payment. After checkout you're redirected back here with the run window open. Access lasts 30 days from the payment date.
Reproducibility-crisis tools accept a paper or biomarker and return a relevance score — that part is commodity. DCFN - Bio is different in what it does with the corpus: graph-native cognitive traversal that distinguishes citation-stale-because-abandoned from citation-stale-because-canonical (obliteration-by-incorporation), surfaces convergence anchors (concepts orbited by multiple research groups without explicit cross-citation), and produces a per-paper reproducibility risk profile in biotech-regulatory vocabulary.
Structural anchors + convergence clusters + untested foundations + recommended directions. Biotech-regulatory vocabulary throughout (TPP, T1-T4, pre-analytical variables, surrogate endpoints, mechanism evidence quality). Downloadable .docx briefing.
Per claimed biomarker / mechanism: method risk profile, foundation health audit (load-bearing vs citation-inherited noise), pre-analytical variable flag (blood storage / fasting / freeze-thaw), reproducibility risk score per cited paper, recommended methodological alternatives where structural evidence supports them, TPP alignment + T1-T4 translational stage mapping, mechanism evidence quality grade.